This study is a prospective randomized trial examining the effect of tranexamic acid (TXA) and aminocaproic acid (ε-Ahx) with local anesthetics and thrombin in all electively created surgical wound beds in hand surgery to provide long term pain relief and decrease the use of postoperative narcotics.

All surgical created wounds for any hand surgery will be treated in a randomized fashion with the following four arms:

1. Bupivacaine + lidocaine
2. Bupivacaine + lidocaine + thrombin
3. Bupivacaine + lidocaine + thrombin + tranexamic acid
4. Bupivacaine + lidocaine + thrombin + aminocaproic acid

All are applied topically to surgical bed prior to closure of skin.

Inclusion Criteria:

• Age 18 or older
• Any patient undergoing elective hand surgery

Exclusion Criteria:

• Any patient with a traumatic or infected open wound (only surgically created wounds will be included)
• History of chronic pain
• History of narcotic addiction
• History of recreational drug dependency
• History of psychiatric pathology
• Allergy or hypersensitivity to local anesthetics, recombinant human thrombin or tranexamic acid
• History of coagulopathy or active thromboembolic disease
• Any patient receiving a supra/infraclavicular block for anesthesia
• Pregnancy
• Hypersensitivity to hamster proteins
• History of seizures
• Significant renal impairment (chronic kidney disease stage 3 or greater)
• History of retinal vascular disease or history of unexplained visual symptoms
• Active upper urinary tract bleeding
• History of known hypercoagulable disorder, prior thromboembolic events, or active clotting disorders
• History of severe hepatic dysfunction (active hepatitis or steatohepatitis, hepatic fibrosis considered cirrhosis)

The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to dtwc@davidchiumd.com. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB